

# Louise Birkedal GlenthÃ¸j

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8914834/publications.pdf>

Version: 2024-02-01

31  
papers

691  
citations

623734

14  
h-index

610901

24  
g-index

31  
all docs

31  
docs citations

31  
times ranked

818  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of remission from the ultra-high risk state for psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 104-112.	1.7	8
2	EPA guidance on treatment of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2021, 64, e21.	0.2	70
3	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. <i>Schizophrenia Bulletin</i> , 2021, 47, 1018-1028.	4.3	10
4	Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis. <i>JAMA Psychiatry</i> , 2021, 78, 753.	11.0	74
5	Global fractional anisotropy predicts transition to psychosis after 12 months in individuals at ultra-high risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2021, 144, 448-463.	4.5	9
6	Changes in negative symptoms are linked to white matter changes in superior longitudinal fasciculus in individuals at ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2021, 237, 192-201.	2.0	6
7	EPA guidance on assessment of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2021, 64, e23.	0.2	94
8	Assessing social skills in individuals at ultra-high risk for psychosis: Validation of the High Risk Social Challenge task (HiSoC). <i>Schizophrenia Research</i> , 2020, 215, 365-370.	2.0	7
9	Basic symptoms influence real-life functioning and symptoms in individuals at high risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 231-240.	4.5	7
10	Supplementary data for a focused review and meta-analysis of 1H-MRS studies on cerebral glutamate and GABA levels in high-risk of psychosis states. <i>Data in Brief</i> , 2020, 28, 104920.	1.0	1
11	Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of 1H-MRS studies. <i>Schizophrenia Research</i> , 2020, 215, 38-48.	2.0	36
12	Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 569-579.	1.5	12
13	Investigating Cognitive and Clinical Predictors of Real-Life Functioning, Functional Capacity, and Quality of Life in Individuals at Ultra-High Risk for Psychosis. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	5
14	Effectiveness of cognitive remediation in the ultra-high risk state for psychosis. <i>World Psychiatry</i> , 2020, 19, 401-402.	10.4	18
15	Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trial. <i>Schizophrenia Research</i> , 2020, 224, 151-158.	2.0	23
16	No Effects of Cognitive Remediation on Cerebral White Matter in Individuals at Ultra-High Risk for Psychosis: A Randomized Clinical Trial. <i>Frontiers in Psychiatry</i> , 2020, 11, 873.	2.6	9
17	Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months. <i>European Psychiatry</i> , 2020, 63, e83.	0.2	7
18	Self-perceived cognitive impairments in psychosis ultra-high risk individuals: associations with objective cognitive deficits and functioning. <i>NPJ Schizophrenia</i> , 2020, 6, 31.	3.6	5

#	ARTICLE	IF	CITATIONS
19	Development of Executive Functions as Reflected in Daily Life Behaviors in Young Adults at Ultra-High Risk for Psychosis: Associations With Symptoms and Functioning. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	1
20	Experiential negative symptoms are more predictive of real-life functional outcome than expressive negative symptoms in clinical high-risk states. <i>Schizophrenia Research</i> , 2020, 218, 151-156.	2.0	19
21	Widespread higher fractional anisotropy associates to better cognitive functions in individuals at ultra-high risk for psychosis. <i>Human Brain Mapping</i> , 2019, 40, 5185-5201.	3.6	22
22	Emotion recognition latency, but not accuracy, relates to real life functioning in individuals at ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2019, 210, 197-202.	2.0	13
23	Validation of the MUSIC Model of Motivation Inventory for use with cognitive training for schizophrenia spectrum disorders: A multinational study. <i>Schizophrenia Research</i> , 2019, 206, 142-148.	2.0	5
24	Non-pharmacological modulation of cerebral white matter organization: A systematic review of non-psychiatric and psychiatric studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 88, 84-97.	6.1	13
25	Examining speed of processing of facial emotion recognition in individuals at ultra-high risk for psychosis: Associations with symptoms and cognition. <i>Schizophrenia Research</i> , 2018, 195, 562-563.	2.0	5
26	White matter maturation during 12 months in individuals at ultra-high risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 65-78.	4.5	23
27	The effect of cognitive remediation in individuals at ultra-high risk for psychosis: a systematic review. <i>NPJ Schizophrenia</i> , 2017, 3, 20.	3.6	62
28	Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 250-258.	4.5	25
29	Course of illness in a sample of patients diagnosed with a schizotypal disorder and treated in a specialized early intervention setting. Findings from the 3.5 year follow-up of the OPUS II study. <i>Schizophrenia Research</i> , 2017, 182, 24-30.	2.0	16
30	Social cognition in patients at ultra-high risk for psychosis: What is the relation to social skills and functioning?. <i>Schizophrenia Research: Cognition</i> , 2016, 5, 21-27.	1.3	46
31	The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 25.	1.6	40